HOWL实时信号 | 通过Getagraph.com最大化利润

购买 114801 min ago

@ $6.85

发出时间: 9 Feb 2024 @ 23:56

回报率: -1.46%

上一信号: Feb 9 - 00:03

上一信号: 出售

回报率: 3.95 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer...

Stats
今日成交量	82 000.00
平均成交量	238 830
市值	288.48M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-0.350 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.43
ATR14	$0.0190 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-04	Atkins Michael B.	Buy	35 000	Stock Option (right to buy)
2024-01-04	Atkins Michael B.	Sell	0	Common Stock
2024-01-02	Trost Timothy W.	Buy	150 000	Stock Option (right to buy)
2024-01-02	Lubman Ellen	Buy	131 900	Stock Option (right to buy)
2024-01-02	Isaacs Randi	Buy	200 000	Stock Option (right to buy)

INSIDER POWER
99.27
Last 97 transactions
Buy: 45 258 272 \| Sell: 143 550 934

音量相关性

長: 0.24 (neutral)

短: -0.36 (neutral)

Signal:(59.175) Neutral

Werewolf Therapeutics, 相关性

10 最正相关
RMRM	0.939
APOP	0.918
FEYE	0.897
SVOK	0.88
TLGT	0.879
SVAC	0.874
GAINL	0.874
PAIC	0.861
SYBX	0.854
TDAC	0.851

10 最负相关
MMAC	-0.959
AMRB	-0.922
BOCH	-0.893
NETE	-0.888
RGP	-0.851
SBBP	-0.823
SHSP	-0.809

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Werewolf Therapeutics, 相关性 - 货币/商品

0.85
( strong )

0.86
( strong )

0.00
( neutral )

0.88
( strong )

0.44
( neutral )

-0.81
( strong negative )

Werewolf Therapeutics, 财务报表

Annual	2023
营收:	$19.94M
毛利润:	$18.18M (91.15 %)
EPS:	$-1.050

FY	2023
营收:	$19.94M
毛利润:	$18.18M (91.15 %)
EPS:	$-1.050

FY	2022
营收:	$16.40M
毛利润:	$13.89M (84.70 %)
EPS:	$-1.790

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-5.57

Financial Reports:

No articles found.

Werewolf Therapeutics,

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.